ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag art dna policy climate change

A young arctic fox on green grass
Arctic Greening Won’t Save the Climate—Here’s Why
Donatella Zona, The Conversation | Mar 30, 2022 | 4 min read
The growing season on the tundra is starting earlier as the planet warms, but the plants aren’t sequestering more carbon, a new study finds.
Speaking of Science
The Scientist | Jan 1, 2012 | 2 min read
January 2012's selection of notable quotes
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Science Museums Exhibit Renewed Vigor
Christine Bahls | Mar 28, 2004 | 10+ min read
Erica P. JohnsonApreschool girl with black braids presses a finger to a disk that twists a brightly lit DNA model, transforming its ladder shape into a double helix. Her head bops from side to side in wonder as the towering DNA coils and straightens. When a bigger boy claims her place, the girl joins meandering moms and dads with their charges as they twist knobs, open flaps, and simply stare at flashing helixes and orange information boards: all a part of the museum exhibit called "Genome: The
Reproductive Research Progresses Despite Restrictions
Sara Latta | Mar 1, 1998 | 8 min read
While the ethics of human cloning has dominated recent discussion of reproductive technologies, research involving human embryos has always been a political hot potato, entangled with the twin issues of abortion and the beginning of human life. Restrictive policies and negative public attitudes surrounding embryo research have made it increasingly difficult for the infertility research community to improve the success rates for assisted reproductive technologies. According to the Centers for Di
Notebook
The Scientist Staff | May 29, 1996 | 6 min read
HERE WE GO AGAIN: More breast cancer genes are likely, says Duke's Futreal. A recent report in Nature Genetics (C. Phelan et al., 13:120-2, 1996) suggests that mutations in BRCA2, the second breast cancer susceptibility gene identified, may not be involved in as many cases of inherited breast cancer as first thought, but it may play a role in some pancreatic cancers. At the same time, the work implies that a third breast cancer gene-and perhaps more-may lurk in human DNA. Researchers at Duke
USPTO Issues Biotech Patent Guidelines
Stephen Hoffert | Jul 5, 1998 | 8 min read
In light of several high-profile court cases on patenting of DNA sequences, the U.S. Patent and Trademark Office (USPTO) in June issued interim guidelines for helping patent examiners determine if the so-called "written description" requirement for patent applications has been met. John J. Doll, director of biotechnology examination at USPTO, says the interim guidelines have become necessary to determine just how court decisions such as University of California Regents v. Eli Lilly and Co. wil
Top 10 Innovations 2016
The Scientist | Dec 1, 2016 | 10+ min read
This year’s list of winners celebrates both large leaps and small (but important) steps in life science technology.
Multiple Investigations
Billy Goodman | Aug 18, 1996 | 10+ min read
Changes In System REHIRED: Following her exoneration, Thereza Imanishi-Kari was named an associate professor at Tufts University. Participants, observers say the case highlighted a need to overhaul the mechanism for dealing with charges of scientific misconduct. The conclusion of the decade-long scientific misconduct case against Thereza Imanishi-Kari-she was exonerated in a June 21 decision of an appeals panel of the Department of Health and Human Services (HHS)-would appear to be a clear-cu

Run a Search

ADVERTISEMENT